Cancer models, research chemicals and reference materials
TRC Cancer research chemicals and analytical standards
From kinase inhibitors, apoptosis inducers and cytokine modulators to isotopes and synthetic chemistry building blocks, TRC supports you from target identification to drug development and toxicology.
From advanced 3D organoids and immuno-oncology models to the largest global repository of cancer lines, ATCC provides an unparalleled collection of cancer tools for basic research and drug discovery.
Explore our range of reference materials for oncology drugs designed for quantitative analysis. Each comes with a detailed COA providing full transparency of product characterisation.
TRC Cancer research chemicals and analytical standards
ATCC Get closer to in vivo
Mikromol API and impurity reference standards
"From early stage drug discovery through to method development, drug substance testing and product release."
Cancer is a complex, multifactorial disease characterised by the unrestrained proliferation of cells which invade normal tissues and organs. Hanahan and Weinberg pioneered modern studies of cancer-related genetic aberrations and epigenetic changes in 2011, when they proposed 10 ‘Hallmarks’ for cancer research. These hallmarks include: evading growth suppressors, avoiding immune destruction, enabling replicative immortality, tumour-promoting inflammation, activating invasion and metastasis, inducing angiogenesis, genome instability and mutation, sustaining proliferative signalling and resisting cell apoptosis. Meanwhile, advances in genomics and biochemistry precipitated identification of key drug targets including cyclin-dependent kinases (CDK) and PARP enzymes, telomerases, p53, as well as RTK’s such as EGFR and VEGF.
Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. We provide industry-leading life science tools - from biologically active small molecules to cellular models, such as classical cancer cell lines and 3D screening platforms for the development of personalised medicines. We also supply API and impurity research chemicals as well as primary pharmaceutical reference standards to support your method development and drug batch release.
Kinase modulators
Kinases are signal transduction enzymes that mediate their actions through phosphorylation and are widely dysregulated in cancer. Discover our large and novel range of kinase inhibitors, including gefitinib and osimertinib.
Apoptosis is a mechanism of cell death with relevance to cancer disease progression as well as treatment design. Discover TRC wide-ranging chemotherapeutics and targeted apoptosis inducers such as Navitoclax.
Angiogenesis is the formation of new blood vessels from preexisting vasculature and occurs during cancer growth and metastasis. Discover TRC angiogenesis regulators and inhibitors, including VEGF targeting API pazopanib.
Cytokines, chemokines and growth factors are central to cell signalling, the tumour microenvironment and cancer. Discover ligands as well as cytokine and receptor modulators such as potent TNFα production inhibitor pomalidomide.
Advances in in vitro and animal modeling of ADMET and mechanistic studies faciliate ever more accurate predictions of drug safety. Discover TRC drug standards, bioactive molecules and SILS including TK inhibitor imatinib.
From advances in target identification to tracing and MS analysis of drug metabolites in ADMET studies. TRC's market-leading SIL standards, including 13C-erlotinib, can help throughout your drug discovery and toxicology journey.
Chemical contamination of soil, water, air and food impacts health on a global scale. TRC supports your environmental research. Discover wide-ranging carcinogens, including nicotine derivates, food and environmental pollutants.
Acquired resistance to EGF receptor inhibitor Osimertinib is a problem for patients with lung cancer. TRC research chemicals were used in an investigation into resistance mechanisms, highlighting a prominent role of AXL/SFK/AKT signalling pathway.
Supporting the development of more effective therapies
Acquired resistance to EGF receptor inhibitors remains an issue causing relapse of lung cancers. TRC research chemicals were used in proteomics work to probe the nature of protein networks that assemble around the EGF receptor in resistant cancers.
TRC research chemicals were used in this novel treatment study
Decades of research aiming to identify new treatments to reduce mortality rates in metastatic uveal melanoma (UM) are still progressing. TRC research chemicals were used in a trial of a promising novel treatment approach using spheroid models of UM.